These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 36437506)

  • 1. Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma.
    Wang X; Yu N; Cheng G; Zhang T; Wang J; Deng L; Li J; Zhao X; Xu Y; Yang P; Bai N; Li Y; Bi N
    Clin Transl Med; 2022 Nov; 12(11):e1116. PubMed ID: 36437506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
    Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML
    JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab.
    Chen B; Liu S; Zhu Y; Wang R; Cheng X; Chen B; Dragomir MP; Zhang Y; Hu Y; Liu M; Li Q; Yang H; Xi M
    Nat Commun; 2024 Mar; 15(1):1919. PubMed ID: 38429311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Burden Monitoring with Circulating Tumor DNA During Treatment in Patients with Esophageal Squamous Cell Carcinoma.
    Morimoto Y; Matsuda S; Kawakubo H; Nakamura K; Kobayashi R; Hisaoka K; Okui J; Takeuchi M; Aimono E; Fukuda K; Nakamura R; Saya H; Nishihara H; Kitagawa Y
    Ann Surg Oncol; 2023 Jun; 30(6):3747-3756. PubMed ID: 36788188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma.
    Wu H; Yu Y; Zheng Q; Liu T; Wu Y; Wang Z; Zheng H; Liu L; Li J
    Radiat Oncol; 2021 Oct; 16(1):207. PubMed ID: 34717670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer.
    Khakoo S; Carter PD; Brown G; Valeri N; Picchia S; Bali MA; Shaikh R; Jones T; Begum R; Rana I; Wotherspoon A; Terlizzo M; von Loga K; Kalaitzaki E; Saffery C; Watkins D; Tait D; Chau I; Starling N; Hubank M; Cunningham D
    Clin Cancer Res; 2020 Jan; 26(1):183-192. PubMed ID: 31852830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma.
    Dai H; Shao YW; Tong X; Wu X; Pang J; Feng A; Yang Z
    Cancer Med; 2020 Mar; 9(5):1628-1637. PubMed ID: 31851786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study of postoperative radiotherapy for locally advanced esophageal squamous cell carcinoma.
    Zhang Z; Xu L; Di X; Zhang C; Ge X; Sun X
    Ann Palliat Med; 2019 Nov; 8(5):708-716. PubMed ID: 31865731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma.
    Cabel L; Jeannot E; Bieche I; Vacher S; Callens C; Bazire L; Morel A; Bernard-Tessier A; Chemlali W; Schnitzler A; Lièvre A; Otz J; Minsat M; Vincent-Salomon A; Pierga JY; Buecher B; Mariani P; Proudhon C; Bidard FC; Cacheux W
    Clin Cancer Res; 2018 Nov; 24(22):5767-5771. PubMed ID: 30054279
    [No Abstract]   [Full Text] [Related]  

  • 10. ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach.
    Nielsen LR; Stensgaard S; Meldgaard P; Sorensen BS
    Cancer Treat Res Commun; 2024; 39():100802. PubMed ID: 38428066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer.
    Azad TD; Chaudhuri AA; Fang P; Qiao Y; Esfahani MS; Chabon JJ; Hamilton EG; Yang YD; Lovejoy A; Newman AM; Kurtz DM; Jin M; Schroers-Martin J; Stehr H; Liu CL; Hui AB; Patel V; Maru D; Lin SH; Alizadeh AA; Diehn M
    Gastroenterology; 2020 Feb; 158(3):494-505.e6. PubMed ID: 31711920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted sequencing of circulating cell-free DNA in stage II-III resectable oesophageal squamous cell carcinoma patients.
    Meng P; Wei J; Geng Y; Chen S; Terpstra MM; Huang Q; Zhang Q; Su Z; Yu W; Su M; Kok K; van den Berg A; Gu J
    BMC Cancer; 2019 Aug; 19(1):818. PubMed ID: 31429737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer.
    Han K; Zou J; Zhao Z; Baskurt Z; Zheng Y; Barnes E; Croke J; Ferguson SE; Fyles A; Gien L; Gladwish A; Lecavalier-Barsoum M; Lheureux S; Lukovic J; Mackay H; Marchand EL; Metser U; Milosevic M; Taggar AS; Bratman SV; Leung E
    J Clin Oncol; 2024 Feb; 42(4):431-440. PubMed ID: 37972346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma.
    Guo JC; Huang TC; Lin CC; Hsieh MS; Chang CH; Huang PM; Lee JM; Hsu FM; Chia-Hsien Cheng J; Wang HP; Yeh KH; Cheng AL; Hsu CH
    J Thorac Oncol; 2015 Oct; 10(10):1481-9. PubMed ID: 26313683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Adenocarcinoma.
    Cabalag CS; Yates M; Corrales MB; Yeh P; Wong SQ; Zhang BZ; Fujihara KM; Chong L; Hii MW; Dawson SJ; Phillips WA; Duong CP; Clemons NJ
    Ann Surg; 2022 Aug; 276(2):e120-e126. PubMed ID: 35737908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
    Li N; Wang BX; Li J; Shao Y; Li MT; Li JJ; Kuang PP; Liu Z; Sun TY; Wu HQ; Ou W; Wang SY
    Cancer; 2022 Feb; 128(4):708-718. PubMed ID: 35076939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy and chemoradiotherapy for postoperative recurrence in patients with esophageal squamous cell carcinoma.
    Liu Q; Tu XH; Yu RX; Wen HY; Guo XG; Ma DY; Jiang KY; Tian D
    Cancer Med; 2024 Aug; 13(16):e70108. PubMed ID: 39161098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
    Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
    PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of circulating tumour DNA after neoadjuvant chemoradiotherapy in patients with locally advanced oesophageal cancer.
    Eyck BM; Jansen MP; Noordman BJ; Atmodimedjo PN; van der Wilk BJ; Martens JW; Helmijr JA; Beaufort CM; Mostert B; Doukas M; Wijnhoven BP; Lagarde SM; van Lanschot JJB; Dinjens WN
    J Pathol; 2023 Jan; 259(1):35-45. PubMed ID: 36196486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic bTMB combined with residual ctDNA improves survival prediction in locally advanced NSCLC patients with chemoradiotherapy and consolidation immunotherapy.
    Wang Y; Wang W; Zhang T; Yang Y; Wang J; Li C; Xu X; Wu Y; Jiang Y; Duan J; Wang L; Bi N
    J Natl Cancer Cent; 2024 Jun; 4(2):177-187. PubMed ID: 39282582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.